Home » Newsletters » BioWorld Science

BioWorld Science

March 9, 2012

View Archived Issues

Novel GlyT1 inhibitors developed

Canadian study assesses involvement of neuroinflammation in healthy aging humans

Agenus and GSK expand license agreement for vaccine adjuvant

FDA clears IND application for phase III trial of melanoma vaccine

Phase III SAR-1118 trial completes enrollment

Palatin Technologies completes enrollment in phase IIb bremelanotide trial

Bayer HealthCare obtains new product approval

Isis launches phase I trial of first-generation antisense drug

Novel candidate schizophrenia therapies patented by Takeda

RaQualia Pharma presents novel sodium channel antagonists

Roche develops new inhibitors of tyrosine-protein kinase BTK

Novel phosphodiesterase 9A inhibitors reported

Celgene completes acquisition

NeuroTherapeutics Pharma divulges new GABA(A) receptor antagonists

Researchers in U.S. design new therapeutics for radiation injury

Benitec Biopharma enters into new licensing agreement

University of Dundee and GSK to target neglected parasitic diseases

Apexigen grants license for APX-004 development in China

Viral Genetics submits pre-IND for Lyme disease treatment

Gene-modified stem cell therapy shows promise to combat HIV infection

Study of AEZS-130 in cancer cachexia begins

Thrombotech clear to test THR-18 in U.S.

Apogenix's phase II trial in glioblastoma multiforme meets primary endpoint

Repligen submits MAA for SecreFlo

Recombinant protein therapy active against HIV in phase II trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan. 13, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for January 13, 2025
Caplyta star shines as J&J takes Intra-Cellular in $14.6B deal
BioWorld
The J.P. Morgan (JPM) Healthcare Conference in San Francisco kicked off with a resounding bang as Johnson & Johnson (J&J) disclosed plans to acquire...
Proteomics study explores how protein changes influence disease
BioWorld Science
Fourteen global pharma companies are getting together to conduct the largest proteomics study to date, analyzing 600,000 blood samples held in the UK Biobank to...
Type 1 diabetes breakthrough? Sana threads key ‘islet,’ SC-451 to advance
BioWorld
Sana Biotechnology Inc. CEO Steve Harr said “cool and transformative science” led to his firm’s latest strides in type 1 diabetes, and the “very generalizable...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.